Candel Therapeutics Overview
Valuation check: CADL's P/E ratio is -7.22, below the Healthcare sector average of 25.72.
Get informed when a big investor buys or sells
+ Follow-7.22
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Candel Therapeutics (CADL) currently reports a P/E ratio of -7.22. That is below the Healthcare sector average of 25.72. Use the charts on this page to explore Candel Therapeutics's P/E ratio history and peer comparisons.
Candel Therapeutics's P/E ratio of -7.22 is lower than the Healthcare sector average of 25.72. That is roughly 128.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Candel Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -7.22, CADL can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -7.22, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.72. From there, open related valuation or income-statement pages for Candel Therapeutics, and consider following CADL for alerts when major investors trade the stock.
Candel Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows -7.22 versus a sector average near 25.72. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CADL with unrelated industries.
